Neuroelectronic market segments Critical industry issues: Educating clinicians, reimbursement by insurance, regulatory hurdles and implantation bias Leading neuroelectronic companies: Medtronic, ANS, Cyberonics, Advanced Bionics, Neuropace
Neural prostheses -- Size of cochlear implant market is $500M in 2003 - $1.6B in 2008), (retinal implants viable market by 2007, 2008)
Neuromodulation -- Use of electronic stimulation to induce and restore desired function (e.g. urinary urge incontinence for spinal chord injury patients) Neural modulation market estimate is $800m in 2004 - $3B in 2008. Deep brain stimulation also growing for Parkinson’s.
Therapeutic stimulation – Stimulators to reduce pain (e.g. Advanced Bionics—Bion)
Neurodiagnostics – Equipment used to read electrical nervous systems
Neural-computer interfaces – Use of nervous system signals to drive external
Addicted to Neurotechnology: A User’s perspective What do a substance abuser and neurotechnology user have in common? According to Jennifer French, a periplegic who uses a neural stimulation system that has allowed her to stand (with a walker) at her wedding and balance on boats, there are a few interesting similarities: both are addicts, both require time to develop that addiction and both are life changing. Her joke excluded, Jennifer is the executive director of the Society To Increase Mobility (STIM) a non-profit that disseminates information about neurotechnology to users. For Jennifer, neurotechnology is not a market, not a product, but a whole new way to increase people’s quality of life. “It is life changing.”
New Neural Stimulation NSF Engineering Research Center Announced
A collaboration among USC, UC Santa Cruz and Caltech in cooperation with AMI has secured $20M in funding over five years.
Wireless Disposable Brain Imaging
10% of the population suffers from sleep apnea, but only 10% even know it. Advanced Brain Monitoring has produced a new disposable brain EEG system (where the electrodes are disposable not the EEG--thanks Chris) that monitors alertness and drowsiness. ABM has received $7M in funding from NIH and DARPA. Their ARES system is inexpensive, non-invasive, 6 channel, bi-directional radio frequency transmission, can be comfortably worn for 8 hours, and is powered by 2 AA batteries.
Check out ABM’s tag line:Brain monitoring in the home, at work and on demand. Neurotechnology VC's
The venture capital discussion focused on the differences between medical device and biopharmaceutical company valuations and exit strategies. Last IPO window for medical device companies was 1996 and most of the those companies have not done well. Last IPO window for biotech was 2000. Valuations have held up better.